Cost effectiveness of innovative anti-cancer drugs and reimbursement decisions in China

•ICERs of anti-cancer drugs were not associated with reimbursement coverage in China.•Incremental QALYs were positively associated with coverage.•Patient population size by cancer type were positively associated with coverage.•Acquisition costs were negatively associated with coverage.•Value-based coverage consideration of anti-cancer drugs should be reinforced.